



FAST  
LABORATORY  
DIAGNOSTICS

OaCP

# COMPANY PROFILE

## INDUSTRY

Diagnostics

## MANAGEMENT TEAM

**CEO | Enrico Di Oto** - Bs, MD, PhD, +17 years in cancer diagnosis

**CTO | Simone Di Giacomo** - PhD, +15 years in R&D

**CMO | Andrea Faviere** - MBA, +10 years in marketing and sales

**CIO | Matteo Allegro** - +10 years in IT

## NETWORK

- **SOSV - The Accelerator VC**
- **Alma Mater Studiorum** - Università di Bologna
- **Fondazione Golinelli**
- **Policlinico S.Orsola-Malpighi** di Bologna
- **ITA** - Italian Trade Agency
- **EIT Health** - European Institute of Innovation & Technology
- **Enterprise Ireland**
- **Shangai Technnology Innovation Center**

## TOP MILESTONES

- Raised USD 330K from VC
- CE-IVD mark
- Growing revenues
- **The global FIRST CE-IVD COVID-19 Nucleic Acid Detection Kit** that simultaneously detect COVID-19 positivity and the presence of its main variants

## OUR STORY

OaCP has been **conceived in 2015** as a project within the Bologna University Entrepreneurship Program (aka Launch Pad).

We **won the first edition of the Launch Pad Program** and enrolled in the **TVLP.co mindset program** in Silicon Valley (Menlo Park, SF).

One year later, OaCP was officially incorporated and was **selected to take part in the RebelBio Accelerator Program in Cork (IE)**. Our company is **headquartered in Ireland with an R&D dept. at the Bologna University**, where we enjoy not only their world-class equipment and facilities but also maintain key **industrial partnerships and collaboration with the University and research groups**.

## WHAT WE DO

- OaCP provides **CE approved and proprietary advanced diagnostic reagents** that make 50% less costly and 97% faster DNA tests for cancer diagnosis using In Situ Hybridization.
- OaCP products also allow **easier and faster RT PCR tests for Viral** (eg. COVID-19), **Microbiological and Cancer analysis**.



## NEED / OPPORTUNITY

The **lack of efficiency of DNA tests** for cancer and infection diseases diagnosis is causing additional **costs** for patients and systems and longer **times to get results**.

## SOLUTION

- OaCP **CE-IVD chemical reagents** that improve DNA reaction efficiency for In situ hybridization.
- OaCP **RT-PCR kits** for a faster, easier and a more reliable COVID-19 testing.

## COMPETITORS



## GO TO MARKET

OaCP is selling to **hospitals, labs, and R&D centers** by using distributors. We have sales representatives in Italy and Japan and we have a **distribution network that covers 17 countries** globally ready to scale.



## CONTACTS

**Enrico Di Oto**  
**+39 320 074 58 78**  
**ceo@oacp.it**

OaCP